Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Paintaud

Showing results (21-30 of 151) with videos related to

Pageof 16
Sort By:
Critical Reviews in Oncology/Hematology|February 9, 2007
Pharmacokinetics of rituximab and its clinical use: thought for the best use?Guillaume Cartron, Hélène Blasco, Gilles Paintaud, et al.
Pharmaceutical Research|September 1, 2005
Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkersMeindert Danhof, Gunnar Alvan, Svein G Dahl, et al.
Virologie (Montrouge, France)|July 6, 2022
Treatment of chronic hepatitis B: virological and pharmacological aspectsTristan Foucault, Lynda Handala, Gilles Paintaud, et al.
Clinical Pharmacokinetics|July 1, 2015
Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid ArthritisDavid Ternant, Theodora Bejan-Angoulvant, Christophe Passot, et al.
Clinical Pharmacokinetics|May 27, 2018
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in HumansDavid Ternant, Nicolas Azzopardi, William Raoul, et al.
Blood|August 5, 2005
Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodiesDavid Ternant, Marc Ohresser, Cécile Thomas, et al.
Joint Bone Spine|February 24, 2012
Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?Denis Mulleman, Emilie Ducourau, Gilles Paintaud, et al.
Bulletin Du Cancer|November 6, 2007
[Target antigens for therapeutic antibodies in oncology: many candidates, few successes]Nicolas Ceze, Alicia Probst, Thierry Lecomte, et al.
Acta Dermato-Venereologica|October 2, 2014
Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic reviewCarole Dannepond, Annabel Maruani, Laurent Machet, et al.
British Journal of Clinical Pharmacology|October 18, 2011
Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphomaDavid Ternant, Guillaume Cartron, Emilie Hénin, et al.
Pageof 16

Showing results (21-30 of 151) with videos related to

Sort By:
Pageof 16
Critical Reviews in Oncology/Hematology|February 9, 2007
Pharmacokinetics of rituximab and its clinical use: thought for the best use?Guillaume Cartron, Hélène Blasco, Gilles Paintaud, et al.
Pharmaceutical Research|September 1, 2005
Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkersMeindert Danhof, Gunnar Alvan, Svein G Dahl, et al.
Virologie (Montrouge, France)|July 6, 2022
Treatment of chronic hepatitis B: virological and pharmacological aspectsTristan Foucault, Lynda Handala, Gilles Paintaud, et al.
Clinical Pharmacokinetics|July 1, 2015
Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid ArthritisDavid Ternant, Theodora Bejan-Angoulvant, Christophe Passot, et al.
Clinical Pharmacokinetics|May 27, 2018
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in HumansDavid Ternant, Nicolas Azzopardi, William Raoul, et al.
Blood|August 5, 2005
Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodiesDavid Ternant, Marc Ohresser, Cécile Thomas, et al.
Joint Bone Spine|February 24, 2012
Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?Denis Mulleman, Emilie Ducourau, Gilles Paintaud, et al.
Bulletin Du Cancer|November 6, 2007
[Target antigens for therapeutic antibodies in oncology: many candidates, few successes]Nicolas Ceze, Alicia Probst, Thierry Lecomte, et al.
Acta Dermato-Venereologica|October 2, 2014
Serum infliximab concentrations in psoriatic patients treated with infliximab: a systematic reviewCarole Dannepond, Annabel Maruani, Laurent Machet, et al.
British Journal of Clinical Pharmacology|October 18, 2011
Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphomaDavid Ternant, Guillaume Cartron, Emilie Hénin, et al.
Pageof 16